To Reveal the True Value of Exact Sciences (NASDAQ:EXAS) Listen to the Highly Respected Company that is the ”Science” behind Exact Sciences

Short Term Target Reaffirmed at $20 … Long Term Looks Dire

Citron is surprised that neither investors nor analysts properly analyzed the important disclosure from Exact on April 27th. Citron notes that the company did not issue a PR for this transaction, but suggests that all investors seeking insight into the company’s prospects had better consider it carefully.